CG Oncology and ArriVent Raise $555M in IPOs
CG Oncology and ArriVent Raise a Combined $555M in IPOs
CG Oncology
CG Oncology plans to use $183.8 million of the net proceeds from its IPO to fund research and development for cretostimogene, as well as manufacturing activities.
The remaining funds will be allocated for working capital, general corporate purposes, and pre-commercial activities.
ArriVent
ArriVent intends to set aside $50 million to $60 million of its IPO proceeds to support NDA activities for furmonertinib, specifically for its use as a first-line therapy for patients with EGFRm NSCLC involving exon 20 insertion mutations.
CG Oncology and ArriVent have successfully raised a combined total of $555 million through their IPOs. CG Oncology plans to allocate a significant portion of its proceeds towards the research and de...